quinvaxem
Vaccineexperimental
A pentavalent vaccine combines five vaccines into one dose. Pentavalent vaccines include:DTwP-HepB-Hib vaccine, used by UNICEF in low/middle income countries DTaP-IPV/Hib vaccine, used in the UK until 2017 DTaP-IPV-HepB vaccine, approved in the US — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
2
Earliest trial started Apr 1, 2010 (NCT01362517)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Tetanus toxinImmunity, active
tetX immunity, active
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
- Diphtheria toxinImmunity, active
Diphtheria toxin immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPentavalent vaccine ↗
Also known as
- quinvaxem
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02408926 | Phase 4 | Apr 1, 2015 | Chulalongkorn University, Institut Pasteur, Thrasher Research Fund, University of Antwerp |
| NCT01917357 | Phase 3 | Sep 1, 2013 | Crucell |
| NCT01357720 | Phase 4 | May 1, 2011 | Crucell |
| NCT01362517 | Phase 3 | Apr 1, 2010 | Crucell, Institut Pasteur |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 3 | 3 | 2 | 2010 |
| Institut Pasteur | Academic/Hospital | 2 | 0 | 2 | 2010 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Thrasher Research Fund | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Antwerp | Academic/Hospital | 1 | 1 | 1 | 2015 |
5 organizations
Page 1 / 1